Cite
HARVARD Citation
Kavanaugh, A. et al. (n.d.). THU0420 Long-Term (104-Week) Efficacy and Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomised, Controlled Trial and Open-Label Extension (Palace 1). Annals of the rheumatic diseases. pp. 350-351. [Online].